A major new analysis suggests that a class of diabetes medication could play a role in protecting the brain from dementia, offering fresh hope for millions of people managing type 2 diabetes alongside concerns about cognitive decline. The findings were published in JAMA Neurology.
Researchers reviewed data from more than 160,000 participants across 26 clinical trials to assess whether glucose-lowering drugs recommended for heart protection could also reduce the risk of dementia. The study found that while most of these treatments did not significantly lower the chances of developing dementia or cognitive impairment, one class of medication – glucagon-like peptide-1 receptor agonists (GLP-1RAs) – showed a clear benefit.
GLP-1RAs are already widely used to manage blood sugar and reduce cardiovascular risks in people with type 2 diabetes. The latest findings indicate that these drugs may also help protect brain function, with trial participants who received them showing a lower rate of all-cause dementia compared to those who received a placebo or standard care.
The study’s authors reported a 45% reduction in dementia risk associated with GLP-1RAs, based on statistical analysis of trial results. However, other glucose-lowering medications, including sodium-glucose cotransporter-2 inhibitors (SGLT2is), did not show the same protective effect. There was no significant evidence that any of the therapies reduced the risk of Alzheimer’s disease or vascular dementia specifically.
These results matter because type 2 diabetes is a well-established risk factor for dementia, possibly due to long-term damage to blood vessels and brain structures. With the global prevalence of dementia rising sharply, especially in ageing populations, any treatment that could slow or prevent cognitive decline is of high public interest.
Despite the promising results for GLP-1RAs, the overall findings were more cautious. Across the broader set of glucose-lowering drugs examined, there was no statistically significant reduction in the risk of dementia. The observed protective effect appeared to be limited to GLP-1RAs alone, not the wider category of cardioprotective diabetes medications.
One possible explanation is the biological action of GLP-1RAs, which may reduce inflammation and oxidative stress in the brain, in addition to improving cardiovascular health. However, researchers also pointed out that the dementia rates in the trials were low and follow-up periods relatively short, meaning that larger and longer-term studies are still needed to confirm the benefits.
Currently, no specific diabetes drug is licensed for dementia prevention, but the findings support the idea that some treatments could offer wider benefits beyond blood sugar control. GLP-1RAs are already used under brand names such as semaglutide and liraglutide and have gained attention for weight management and heart protection.
This latest evidence may influence prescribing decisions, particularly for patients at higher risk of cognitive decline. However, experts agree that more targeted trials are needed, especially those focusing specifically on older adults or those already showing early signs of memory loss.